Developments in hematopoietic stem-cell transplantation in the treatment of autoimmune diseases

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F02%3A00003703" target="_blank" >RIV/00216208:11120/02:00003703 - isvavai.cz</a>
Result on the web
<a href="http://www.ima.org.il/imaj/ar02apr-8.pdf" target="_blank" >http://www.ima.org.il/imaj/ar02apr-8.pdf</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Developments in hematopoietic stem-cell transplantation in the treatment of autoimmune diseases
Original language description
Intractable forms of autoimmune diseases follow a rapid course, with a significantly shortened life. expectancy sometimes comparable to that of malignant diseases. Immunoablative therapy; including high dose cytotoxic agents and hematopoietic autologousstem-cell rescue, was recently introduced as an aggressive approach to treat autoimmune diseases that-have a rapid course and are resistant to conventional therapy. The most frequent indication for this type of treatment is multiple sclerosis, seconded by systemic sclerosis. The results of immunoablative treatment with documented responses in both diseases are encouraging. The data are mature enough to begin comparative randomized studies of immunoablative versus conventional treatment to validate the benefit, of the aggressive approach. A randomized trial involving SSc was recently launched (ASTIS) and a trial involving MS is in preparation: Considerably less experience with; immunoablative treatment has, been gained in systemic lupus
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Publication year
2002
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)